Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Comparison of the Effects of Dovitinib and Bevacizumab on Reducing Neovascularization in an Experimental Rat Corneal Neovascularization Model

Sahan, Berna MD*; Ciftci, Ferda MD*; Eyuboglu, Signem PhD; Yaba Ucar, Aylin PhD; Yilmaz, Bayram PhD; Yalvac, Belkıs Ilgaz MD*

doi: 10.1097/ICO.0000000000002012
Basic Investigation
Buy

Purpose: To compare the inhibitory effects of dovitinib and bevacizumab for treatment of corneal neovascularization (CNV).

Methods: Thirty-nine adult female Sprague Dawley rats weighing 180 to 250 g were used. CNV was induced by silver nitrate in the right eye of each rat. After the chemical burn, the animals were randomized into 5 groups. Group 1 did not receive any chemical substance. Group 2 received dimethyl sulfoxide, group 3 received bevacizumab 5 mg/mL, group 4 received dovitinib 5 mg/mL, and group 5 received bevacizumab 5 mg/mL + dovitinib 5 mg/mL topically administered twice daily for 14 days. On the 14th day, slit-lamp examination was performed, and anterior segment photographs were taken. The corneal neovascular area was measured on photographs as the percentage of the cornea's total area using computer imaging analysis. The corneal sections were stained with hematoxylin and eosin for histopathological examination.

Results: A statistically significant decrease in the percentage of CNV was found in all treatment groups (group 3, group 4, and group 5) compared with the control group (group 1) (P < 0.01). A statistically significant difference in the percentage of CNV was found among group 3, group 4, and group 5 (P = 0.003). The percentage of CNV in group 4 was significantly higher than that in group 3 and group 5 (P1 = 0.004; P2 = 0.006). There was no statistically significant difference in the percentage of CNV between group 3 and group 5 (P = 0.228).

Conclusions: Dovitinib is a newly developed multitargeted tyrosine kinase inhibitor. Topical administration of dovitinib effectively inhibited CNV, but this effect of dovitinib was found less than topical bevacizumab.

*Department of Ophthalmology, School of Medicine, Yeditepe University, Istanbul, Turkey;

Department of Physiology, School of Medicine, Istinye University, Istanbul,Turkey;

Department of Physiology, School of Medicine, Yeditepe University, Istanbul, Turkey; and

Department of Histology and Embyrology, School of Medicine, Yeditepe UNiversity, Istanbul, Turkey.

Correspondence: Berna Sahan, MD, Department of Ophthalmology, School of Medicine, Yeditepe University, Sakir Kesebir Sokak No: 28, 34349 Balmumcu-Besiktas, Istanbul, Turkey (e-mail: bernasahan@yahoo.com).

The authors have no funding or conflicts of interest to disclose.

Received October 02, 2018

Received in revised form April 09, 2019

Accepted April 17, 2019

Online date: June 5, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.